There are just a few definitions by which traders outline penny shares. Some stick with the concept that penny shares are those who commerce under $1. This was the standard definition of a penny inventory, and the one you’re almost certainly to see. Others use market capitalization.
There stays no consensus as to the “true” definition of a penny inventory. However they continue to be common, as they’re cheap and sometimes risky. That volatility signifies that traders can probably obtain very fast positive aspects. Sure, that’s in fact balanced by substantial threat, however the truth stays that penny shares will at all times be alluring.
My guess is that penny shares might see an upsurge in reputation within the close to future: Now that cryptomania has cooled, traders with larger threat tolerance might pivot into penny shares. If that’s the case, such demand might elevate costs shortly.
Whether or not that occurs or not, penny shares have already got the ability to rise shortly. The listing under will embrace these which have the potential for 10X positive aspects. Let’s dive in.
- Protagenic Therapeutics (NASDAQ:PTIX)
- Thoughts Medication (NASDAQ:MNMD)
- Conformis (NASDAQ:CFMS)
- Senseonics (NYSEAMERICAN:SENS)
- Sesen Bio (NASDAQ:SESN)
- NexGen Vitality (NYSEAMERICAN:NXE)
- Elys Sport Expertise Corp. (NASDAQ:ELYS)
Penny Shares: Protagenic Therapeutics (PTIX)
Historically, biotech firms search to commercialize therapeutics which alleviate issues associated to bodily well being. However just lately, there was an growing deal with the thoughts, stress and temper issues, which wasn’t actually the case just a few years in the past.
That’s the place Protagenic Therapeutics focuses its efforts. The corporate engages within the growth of therapeutics for stress-related neuropsychiatric and temper issues. Recent studies by the Cleveland Clinic point out that stress is on the rise, possible confirming what many already suspected — the pandemic has result in larger stress.
It is a sturdy indication that Protagenic Therapeutics may very well be pivotal in psychological well being therapeutics sooner or later. The corporate is particularly looking for to dominate a goal promote it estimates at $20 billion for its lead candidate, PT00114.
That lead molecule has proven sturdy security and efficacy in preclinical fashions, and needs to be in a Section I/IIa trial by Q3 of this 12 months. PT00114 has proven efficacy within the “reversal of melancholy, stress-exacerbated anxiousness, extreme startle, drug looking for, and opioid withdrawal.” If PT00114, as the corporate expects, receives Breakthrough Designation from the FDA it’s simple to see the way it might certainly multiply in value 10X.
Thoughts Medication (MNMD)
Thoughts Medication is, like Protagenic Therapeutics, targeted on the event of neuropharmaceuticals. The corporate, nonetheless, offers with psychedelics.
It will have been far more troublesome, if not not possible, to search out an funding like Thoughts Medication a decade in the past. A part of Thoughts Medication’s attract is its novelty and potential for fast positive aspects that it brings. Buyers are conscious of MNMD inventory and what it’s probably providing from a threat/reward standpoint. The inventory has gained vital traction since mid-September. It has risen from 33 cents at the moment, to only underneath $4 per share now. And given the velocity with which biotech firms rise upon assembly regulatory approval, it isn’t exhausting to think about that MNMD inventory might multiply by 10 instances from its present value.
Thoughts Medication presents experiential remedy wherein LSD is administered to supply a psychedelic impact underneath medical supervision. Sufferers obtain remedy on this setting to assist them cope with psychological well being points. The corporate is targeted on treating anxiousness, habit, and grownup ADHD. It is also growing and researching novel compounds on this new space.
Thoughts Medication sees the addressable market as being one that might develop to $16 trillion in size by 2030. The corporate’s experiential LSD therapies are presently in Section 2b. If Thoughts Medication actually establishes itself because the pioneer on this area, there may be nearly little question it should return 10X positive aspects to traders who’re on board now.
Penny Shares: Conformis (CFMS)
Conformis is an organization that develops, manufactures, and sells replacement joints. Particularly, Conformis makes alternative knee and hip joints. Due to this fact, one catalyst for Conformis is the growing older inhabitants.
Nonetheless, the monetary information for Conformis is considerably combined. Q1 complete and product revenues each decreased by 16% in Q1 on a year-over-year foundation. Nonetheless, Hip System income increased by 49% in the identical interval. Gross margins elevated barely, to 45%, as properly.
The corporate additionally raised $85 million by way of a typical inventory providing giving it funds to pursue additional development and growth.
The funding thesis for Conformis is comparatively simple. It’s cheap at $1.17, the corporate serves an growing older inhabitants with growing demand for joint replacements, and elective surgical procedures needs to be growing as Covid-19 wanes.
Conformis derives roughly 85% of its enterprise from the U.S. which is shortly rising from the pandemic. Once more, meaning elective surgical procedures can be on the rise.
Simply as there may be an growing demand for joint replacements, so too is there a rising demand for diabetes administration options. That’s the place Senseonics might certainly make traders sturdy returns within the coming quarters and years.
Senseonics Holdings has created the primary long-term, steady glucose monitoring system for managing diabetes. The system consists of a sensor (implanted underneath the pores and skin), a detachable transmitter which sends data each 5 minutes, and a cellular app for customers to view their knowledge at any time.
Sadly, as many readers can be conscious, diabetes is on the rise within the U.S. and globally.
Globally, the variety of folks with diabetes elevated from 108 million to 422 million between 1980 and 2014 based on the World Well being Group. And up to date estimates by the CDC point out that 10.5% of the U.S. population presently has diabetes.
Corporations which may greatest assist sufferers handle the illness stand to learn probably the most. Senseonics just lately launched outcomes from the PROMISE study which demonstrated the accuracy of its 180 day steady glucose monitoring system.
SENS inventory presently trades for roughly $3.60 per share and has already multiplied in worth in 2021. In early January, shares traded for underneath $1. It’s clear that there’s a number of room for SENS inventory to maneuver upward and now is a brilliant time to determine a place.
Penny Shares: Sesen Bio (SESN)
Sesen Bio might quickly rise above the $5 penny inventory categorization. SESN shares’ value chart signifies a inventory that has been rising steadily all through 2021. Shares started the 12 months at $1.30 and have moved upward to their present value of $4.16 fairly predictably. It does appear to be a inventory with much less volatility than many different penny shares which is often enticing.
The corporate develops focused protein therapeutics to be used within the battle in opposition to most cancers. The corporate’s protein molecule therapeutics selectively and broadly goal and kill most cancers cells whereas minimizing poisonous results on wholesome cells.
Sesen Bio’s most viable path towards 10X positive aspects comes from its Vicineum remedy which is being evaluated in Section-3 trials for efficacy in opposition to bladder most cancers. Additional, the corporate believes that Vicineum can also have efficacy within the remedy of head and neck most cancers. Sesen Bio accomplished a Section-2 trial within the U.S. for that objective which confirmed sufferers had been 71% recurrence-rate free.
Vicineum can be being evaluated along side therapies from AstraZeneca (NASDAQ:AZN) giving it a number of paths to success shifting ahead.
Sesen Bio’s most up-to-date investor presentation signifies that Vicineum might see regulatory approval within the U.S. this 12 months and in 2022 in Europe. That very same presentation additionally suggests Vicineum might even see peak revenues of as excessive as $3 billion shifting ahead.
NexGen Vitality (NXE)
NexGen Vitality takes this text out of Biotech and healthcare penny shares, and into the mining sector.
The corporate is a uranium exploration and growth firm situated in British Columbia. Uranium in all probability doesn’t instantly deliver clear power to thoughts, however NexGen Vitality is squarely advertising and marketing itself towards that future.
Uranium is utilized in fueling nuclear reactors, which have the aptitude of lowering CO2 emissions on a worldwide scale. The manufacturing of nuclear power fueled by uranium removes over 100 million automobile equivalents of CO2 yearly. NexGen Vitality anticipates it should eradicate 70 million automobile equivalents of CO2 yearly by producing the uranium which fuels nuclear reactors.
There are broad indications that the U.S. and Europe will each be looking for to develop nuclear power manufacturing, which can improve the demand for uranium. The present uranium provide hole might improve multiple-fold over the approaching many years which implies exploration and manufacturing firms might have a commodity on their arms that might shortly improve in worth. There was a uranium bull cycle between 2001 and 2007 which noticed costs improve by larger than 2,000%. Uranium appears to be like to be entering another such cycle that means fast positive aspects could also be on the horizon.
Buyers are more and more trying to commodity markets as a bulwark in opposition to inflation issues, and NexGen Vitality is sitting on the biggest development-stage uranium deposit on this planet within the Rook I Mission in Saskatchewan, Canada.
Penny Shares: Elys Sport Expertise Corp. (ELYS)
Elys Sport Expertise is an organization within the quickly rising e-sports, on-line gaming and playing niches. The corporate operates retail and i-Gaming betting and on line casino companies in Austria, Italy, Latin America, and North America. It’s launching U.S. operations in 2021.
The corporate has grown quick over the past 12 months. It oversaw $575 million in wagers over that interval, and $37 million in revenues, a rise of 44%. Within the U.S., 50% of the inhabitants is anticipated to have entry to sports activities playing by 2025. Elys Sport expertise hopes to take a slice of the $7 billion in anticipated revenues from that development.
The corporate desires to promote its expertise suite to playing firms which can use the expertise for the retail betting client. It’s advertising and marketing itself to different B2B on line casino firms as a plug-and-play platform which can be utilized to arrange playing operations for patrons resembling casinos and their retail clients.
On Penny Shares and Low-Quantity Shares: With solely the rarest exceptions, InvestorPlace doesn’t publish commentary about firms which have a market cap of lower than $100 million or commerce lower than 100,000 shares every day. That’s as a result of these “penny shares” are steadily the playground for rip-off artists and market manipulators. If we ever do publish commentary on a low-volume inventory that could be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this truth and warn readers of the dangers.
Learn Extra: Penny Shares — How to Profit Without Getting Scammed
On the date of publication, Alex Sirois didn’t have (both instantly or not directly) any positions within the securities talked about on this article. The opinions expressed on this article are these of the author, topic to the InvestorPlace.com Publishing Guidelines.
Alex Sirois is a contract contributor to InvestorPlace whose private inventory investing model is targeted on long-term, buy-and-hold, wealth-building inventory picks. Having labored in a number of industries from e-commerce to translation to training and using his MBA from George Washington College, he brings a various set of expertise by means of which he filters his writing.”